Sign In
Buy PACB
$1.15
-0.0350 (-2.95%)
At Close: Aug 10, 2026
HiFi Solves Consortium Publishes First Major Study Demonstrating the Clinical Research Power of PacBio HiFi Genomes
09:05am, Wednesday, 05'th Nov 2025
New multi-center study identifies 100% of clinically relevant variants in the study, including those not detected by short-read sequencing technologies, positioning HiFi as the bridge between research
Pacific Biosciences (PACB) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
10:15am, Tuesday, 04'th Nov 2025
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Pacific Biosciences (PACB), delve into some of its key metrics to gain a deeper insight into the company's potential performance
PacBio Supports Berry Genomics in Achieving First Regulatory Approval for Clinical Long-Read Sequencing in China
09:05am, Tuesday, 04'th Nov 2025
NMPA approval on the Sequel II CNDx system enables clinicians in China to harness PacBio HiFi sequencing for challenging conditions, with initial offering for thalassemia NMPA approval on the Sequel I
Sumitomo Mitsui Trust Group Inc. Trims Position in Pacific Biosciences of California, Inc. $PACB
04:06am, Thursday, 30'th Oct 2025
Sumitomo Mitsui Trust Group Inc. cut its holdings in shares of Pacific Biosciences of California, Inc. (NASDAQ: PACB) by 3.6% during the undefined quarter, according to its most recent Form 13F filing
Pacific Biosciences of California (PACB) Stock Drops Despite Market Gains: Important Facts to Note
07:16pm, Tuesday, 28'th Oct 2025
Pacific Biosciences of California (PACB) concluded the recent trading session at $1.97, signifying a -5.74% move from its prior day's close.
PacBio to Report Third Quarter 2025 Financial Results on November 5, 2025
04:05pm, Wednesday, 22'nd Oct 2025
MENLO PARK, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2025 financial results on Wedne
PacBio Aims to Expand Multiomic Capabilities Via Latest Innovations
11:11am, Monday, 20'th Oct 2025
PACB unveils new SPRQ-Nx chemistry to cut sequencing costs and boost multiomic features on Revio and Vega.
Pacific Biosciences of California (PACB) Sees a More Significant Dip Than Broader Market: Some Facts to Know
07:16pm, Tuesday, 14'th Oct 2025
In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.59, marking a -1.85% move from the previous day.
PacBio Announces Major Advances for Revio and Vega to Lower Genome Cost and Expand Multiomic Capabilities
06:05am, Tuesday, 14'th Oct 2025
New SPRQ-Nx chemistry designed to deliver the most complete view of the genome for less than $300 at scale New SPRQ-Nx chemistry designed to deliver the most complete view of the genome for less than
PacBio HiFi Technology Selected as Core Platform for South Korea's National Pangenome Project
09:05am, Monday, 13'th Oct 2025
More than 1,000 Korean genomes to be sequenced for global reference standards, advancing disease research and precision medicine More than 1,000 Korean genomes to be sequenced for global reference sta
Here's Why You Should Retain PacBio Stock in Your Portfolio for Now
11:06am, Friday, 10'th Oct 2025
PACB's Q2 beat, expanding Revio and Vega systems and growing clinical traction highlight its innovation-led recovery despite longer purchasing cycles.
PacBio Stock Dips Despite Announcing Expanded Partnership With seqWell
01:46pm, Wednesday, 08'th Oct 2025
PACB expands seqWell partnership to enhance its sequencing workflow offerings with a new multiplexing kit.
Long Life Family Study Taps PacBio HiFi Sequencing to Unlock Genetic and Epigenetic Clues to Exceptional Longevity
09:05am, Wednesday, 08'th Oct 2025
Up to 7,800 whole genomes and epigenomes to be sequenced on PacBio's Revio system, powering one of the largest studies of healthy aging to date Up to 7,800 whole genomes and epigenomes to be sequenced
PacBio Expands Partnership with seqWell to Bring Scalable Long Read Sample Prep to More Labs
09:05am, Tuesday, 07'th Oct 2025
Highly scalable, cost-effective LongPlex™ kit delivers streamlined tagmentation and multiplexing for low-pass whole genome sequencing, plasmid resequencing, and microbial sequencing Highly scalable,
Why Pacific Biosciences of California (PACB) Outpaced the Stock Market Today
07:16pm, Monday, 06'th Oct 2025
In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.52, marking a +2.01% move from the previous day.
